Related Experiment Video
Updated: Jun 28, 2026

Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
The role of the CAG repeat androgen receptor polymorphism in andrology
1Institute of Reproductive Medicine, Universitätsklinikum Münster, Münster, Germany.
Abstract:
A dysfunctional androgen receptor is able to cause variable phenotypes of androgen insensitivity or androgenicity in humans. In addition, also a polymorphism, the CAG repeat polymorphism in exon 1 of the androgen receptor gene (CAG)n, modulates androgen effects: androgen-induced target activities are attenuated corresponding to the length of triplet residues. Clinically, the (CAG)n polymorphism causes marked modulations of androgenicity in eugonadal men in various tissues and psychological traits and may cause the clinical picture of hypogonadism in the presence of normal testosterone concentrations. Also pharmacogenetic implications might exist in this regard: there appears to be a significant role of testosterone treatment of hypogonadal men as treatment effects have been demonstrated to be modulated by the number of (CAG)n in retrospective approaches.
Insights
The androgen receptor gene's CAG repeat polymorphism influences androgen effects, potentially causing hypogonadism even with normal testosterone. This genetic variation also affects testosterone replacement therapy outcomes in hypogonadal men.
Area of Science:
- Genetics
- Endocrinology
- Molecular Biology
Background:
- Androgen receptor (AR) dysfunction leads to androgen insensitivity or androgenicity.
- The CAG repeat polymorphism in exon 1 of the AR gene, denoted as (CAG)n, modulates androgen-induced activities.
- The length of the (CAG)n repeat inversely correlates with androgenic effects.
Purpose of the Study:
- To investigate the clinical and pharmacogenetic implications of the (CAG)n polymorphism.
- To understand how (CAG)n length affects androgenicity in eugonadal men.
- To explore the role of (CAG)n in modulating testosterone treatment response.
Main Methods:
- Analysis of the CAG repeat polymorphism in the androgen receptor gene.
- Clinical assessment of androgenic phenotypes and psychological traits.
- Retrospective analysis of testosterone treatment outcomes in hypogonadal men.
Main Results:
- The (CAG)n polymorphism significantly modulates androgenicity in various tissues and psychological traits in eugonadal men.
- Longer (CAG)n repeats are associated with attenuated androgenic effects.
- The number of (CAG)n repeats influences the effectiveness of testosterone replacement therapy in hypogonadal men.
Conclusions:
- The (CAG)n polymorphism is a key determinant of androgen action and clinical presentation.
- This genetic variation has significant implications for diagnosing conditions like hypogonadism and for personalized testosterone therapy.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
The Y Chromosome Determines Maleness
Evolution
Around 300 million years ago, the two sex chromosomes diverged from two identical autosomal chromosomes. Over time, the Y chromosome has lost most of its genes, shrinking in size. Today,...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Epigenetic Regulation

